SAB Biotherapeutics, Inc. — Director's Dealing 2021

Nov 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SAB Biotherapeutics, Inc. (SABS)
CIK: 0001833214
Period of Report: 2021-11-17

Reporting Person: Beyer Russell P (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-17	Employee Stock Option (right to buy)	$11.17	A	110000	Acquired	2031-11-17	Common Stock (110000)	Direct

Footnotes

F1: Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.